Alzheimer’s disease is triggered by the deposition of insoluble extracellular b-amyloid (Ab) plaque, and MT2A is capable of protecting against Ab aggregation and toxicity for therapeutic approach to Alzheimer’s disease [10]. This evidence concerns the gene MT2A and Alzheimer disease.